Trial Profile
Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs ET1402L1 CART (Primary) ; ET1402L1 CART (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Aeon Therapeutics
- 27 Jun 2019 Status changed from recruiting to discontinued.
- 05 Sep 2018 Results published in the Eureka Therapeutics Media Release
- 05 Sep 2018 Acording to Eureka Therapeutics media release, today announced preliminary safety and clinical results from this study. The data was presented today in the late-breaking abstracts session of the CAR-TCR Summit in Boston, Massachusett.